Variants of Interest from a Pooled Analysis of Subjects Who Did Not Achieve an SVR in Phase 2 and 3 Studies.

aReplicon IC50 values are the mean from at least three independent experiments with fold-change relative to wild-type (WT) replicon cells. The mean (SD) IC50 value of telaprevir in G1b WT (mADE) replicon cells is 0.482 (0.122) µM (n = 15). In G1a WT replicon the mean (SD) IC50 value of telaprevir is 0.961 (0.132) µM (n = 8).
bNumerator is number of subjects that possess the given variant; denominator is total count of subjects that have sequence data available at that position.
cTreatment-Failure Occurrence indicates the number of subjects in TPR or T/P containing groups from Phase 2 and 3 studies who did not achieve an SVR that had the given variant at the treatment-failure timepoint. The denominator is the total number of subjects from Phase 2 and 3 studies who did not achieve an SVR with treatment-failure timepoint sequencing data available.
dThe value tests for enrichment of the variant in the treatment-failure population (Alpha[Bonferroni corrected]: 1a, 0.0000919; 1b, 0.000102).
eWas determined in replicon 1b.
fThe replicon IC50 is greater than 30 µM, the maximum concentration of telaprevir used in the assay.